Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Dynamic reorganisation of intermediate filaments coordinates early B-cell activation.

Tsui C, Maldonado P, Montaner B, Borroto A, Alarcon B, Bruckbauer A, Martinez-Martin N, Batista FD.

Life Sci Alliance. 2018 Aug 20;1(5):e201800060. doi: 10.26508/lsa.201800060. eCollection 2018 Oct.

2.

Initiation of Antiviral B Cell Immunity Relies on Innate Signals from Spatially Positioned NKT Cells.

Gaya M, Barral P, Burbage M, Aggarwal S, Montaner B, Warren Navia A, Aid M, Tsui C, Maldonado P, Nair U, Ghneim K, Fallon PG, Sekaly RP, Barouch DH, Shalek AK, Bruckbauer A, Strid J, Batista FD.

Cell. 2018 Jan 25;172(3):517-533.e20. doi: 10.1016/j.cell.2017.11.036. Epub 2017 Dec 14.

3.

Increased Vascular Permeability in the Bone Marrow Microenvironment Contributes to Disease Progression and Drug Response in Acute Myeloid Leukemia.

Passaro D, Di Tullio A, Abarrategi A, Rouault-Pierre K, Foster K, Ariza-McNaughton L, Montaner B, Chakravarty P, Bhaw L, Diana G, Lassailly F, Gribben J, Bonnet D.

Cancer Cell. 2017 Sep 11;32(3):324-341.e6. doi: 10.1016/j.ccell.2017.08.001. Epub 2017 Sep 1.

4.

The Small Rho GTPase TC10 Modulates B Cell Immune Responses.

Burbage M, Keppler SJ, Montaner B, Mattila PK, Batista FD.

J Immunol. 2017 Sep 1;199(5):1682-1695. doi: 10.4049/jimmunol.1602167. Epub 2017 Jul 26.

5.

A switch from canonical to noncanonical autophagy shapes B cell responses.

Martinez-Martin N, Maldonado P, Gasparrini F, Frederico B, Aggarwal S, Gaya M, Tsui C, Burbage M, Keppler SJ, Montaner B, Jefferies HB, Nair U, Zhao YG, Domart MC, Collinson L, Bruckbauer A, Tooze SA, Batista FD.

Science. 2017 Feb 10;355(6325):641-647. doi: 10.1126/science.aal3908.

6.

Host response. Inflammation-induced disruption of SCS macrophages impairs B cell responses to secondary infection.

Gaya M, Castello A, Montaner B, Rogers N, Reis e Sousa C, Bruckbauer A, Batista FD.

Science. 2015 Feb 6;347(6222):667-72. doi: 10.1126/science.aaa1300.

7.

The actin and tetraspanin networks organize receptor nanoclusters to regulate B cell receptor-mediated signaling.

Mattila PK, Feest C, Depoil D, Treanor B, Montaner B, Otipoby KL, Carter R, Justement LB, Bruckbauer A, Batista FD.

Immunity. 2013 Mar 21;38(3):461-74. doi: 10.1016/j.immuni.2012.11.019. Epub 2013 Mar 14.

8.

Asymmetric segregation of polarized antigen on B cell division shapes presentation capacity.

Thaunat O, Granja AG, Barral P, Filby A, Montaner B, Collinson L, Martinez-Martin N, Harwood NE, Bruckbauer A, Batista FD.

Science. 2012 Jan 27;335(6067):475-9. doi: 10.1126/science.1214100.

9.

DNA breakage and cell cycle checkpoint abrogation induced by a therapeutic thiopurine and UVA radiation.

Brem R, Li F, Montaner B, Reelfs O, Karran P.

Oncogene. 2010 Jul 8;29(27):3953-63. doi: 10.1038/onc.2010.140. Epub 2010 May 3.

10.

Reactive oxygen-mediated damage to a human DNA replication and repair protein.

Montaner B, O'Donovan P, Reelfs O, Perrett CM, Zhang X, Xu YZ, Ren X, Macpherson P, Frith D, Karran P.

EMBO Rep. 2007 Nov;8(11):1074-9. Epub 2007 Oct 12.

11.

Novel DNA lesions generated by the interaction between therapeutic thiopurines and UVA light.

Zhang X, Jeffs G, Ren X, O'Donovan P, Montaner B, Perrett CM, Karran P, Xu YZ.

DNA Repair (Amst). 2007 Mar 1;6(3):344-54. Epub 2006 Dec 22.

PMID:
17188583
12.

Proteomic analysis of prodigiosin-induced apoptosis in a breast cancer mitoxantrone-resistant (MCF-7 MR) cell line.

Monge M, Vilaseca M, Soto-Cerrato V, Montaner B, Giralt E, Pérez-Tomás R.

Invest New Drugs. 2007 Feb;25(1):21-9.

PMID:
16633713
13.

Cell cycle arrest and proapoptotic effects of the anticancer cyclodepsipeptide serratamolide (AT514) are independent of p53 status in breast cancer cells.

Soto-Cerrato V, Montaner B, Martinell M, Vilaseca M, Giralt E, Pérez-Tomás R.

Biochem Pharmacol. 2005 Dec 19;71(1-2):32-41. Epub 2005 Nov 18.

PMID:
16298346
14.

Azathioprine and UVA light generate mutagenic oxidative DNA damage.

O'Donovan P, Perrett CM, Zhang X, Montaner B, Xu YZ, Harwood CA, McGregor JM, Walker SL, Hanaoka F, Karran P.

Science. 2005 Sep 16;309(5742):1871-4.

15.

DNA interaction and dual topoisomerase I and II inhibition properties of the anti-tumor drug prodigiosin.

Montaner B, Castillo-Avila W, Martinell M, Ollinger R, Aymami J, Giralt E, Pérez-Tomás R.

Toxicol Sci. 2005 Jun;85(2):870-9. Epub 2005 Mar 23.

PMID:
15788728
16.

High cytotoxic sensitivity of the human small cell lung doxorubicin-resistant carcinoma (GLC4/ADR) cell line to prodigiosin through apoptosis activation.

Llagostera E, Soto-Cerrato V, Joshi R, Montaner B, Gimenez-Bonafé P, Pérez-Tomás R.

Anticancer Drugs. 2005 Apr;16(4):393-9.

PMID:
15746575
17.

AT514, a cyclic depsipeptide from Serratia marcescens, induces apoptosis of B-chronic lymphocytic leukemia cells: interference with the Akt/NF-kappaB survival pathway.

Escobar-Díaz E, López-Martín EM, Hernández del Cerro M, Puig-Kroger A, Soto-Cerrato V, Montaner B, Giralt E, García-Marco JA, Pérez-Tomás R, Garcia-Pardo A.

Leukemia. 2005 Apr;19(4):572-9.

PMID:
15744353
18.

Mitochondria-mediated apoptosis operating irrespective of multidrug resistance in breast cancer cells by the anticancer agent prodigiosin.

Soto-Cerrato V, Llagostera E, Montaner B, Scheffer GL, Perez-Tomas R.

Biochem Pharmacol. 2004 Oct 1;68(7):1345-52.

PMID:
15345324
19.

Prodigiosin induces apoptosis by acting on mitochondria in human lung cancer cells.

Llagostera E, Soto-Cerrato V, Montaner B, Pérez-Tomás R.

Ann N Y Acad Sci. 2003 Dec;1010:178-81.

PMID:
15033716
20.

The prodigiosins, proapoptotic drugs with anticancer properties.

Pérez-Tomás R, Montaner B, Llagostera E, Soto-Cerrato V.

Biochem Pharmacol. 2003 Oct 15;66(8):1447-52. Review.

PMID:
14555220
21.

Prodigiosin induces apoptosis of B and T cells from B-cell chronic lymphocytic leukemia.

Campàs C, Dalmau M, Montaner B, Barragán M, Bellosillo B, Colomer D, Pons G, Pérez-Tomás R, Gil J.

Leukemia. 2003 Apr;17(4):746-50.

PMID:
12682632
22.

Effects of the proapoptotic drug prodigiosin on cell cycle-related proteins in Jurkat T cells.

Pérez-Tomás R, Montaner B.

Histol Histopathol. 2003 Apr;18(2):379-85. doi: 10.14670/HH-18.379.

PMID:
12647787
23.

The prodigiosins: a new family of anticancer drugs.

Montaner B, Pérez-Tomás R.

Curr Cancer Drug Targets. 2003 Feb;3(1):57-65. Review.

PMID:
12570661
24.

Prodigiosin induces caspase-9 and caspase-8 activation and cytochrome C release in Jurkat T cells.

Montaner B, Perez-Tomas R.

Ann N Y Acad Sci. 2002 Nov;973:246-9.

PMID:
12485870
25.

Peptide dendrimers based on polyproline helices.

Crespo L, Sanclimens G, Montaner B, Pérez-Tomás R, Royo M, Pons M, Albericio F, Giralt E.

J Am Chem Soc. 2002 Jul 31;124(30):8876-83.

PMID:
12137542
26.

The cytotoxic prodigiosin induces phosphorylation of p38-MAPK but not of SAPK/JNK.

Montaner B, Pérez-Tomás R.

Toxicol Lett. 2002 Mar 24;129(1-2):93-8.

PMID:
11879978
27.

Transforming growth factor-alpha precursors in human colon carcinoma cells.

Asbert M, Montaner B, Pérez-Tomás R.

Dig Dis Sci. 2001 Jun;46(6):1157-62.

PMID:
11414287
28.

Prodigiosin-induced apoptosis in human colon cancer cells.

Montaner B, Pérez-Tomás R.

Life Sci. 2001 Mar 16;68(17):2025-36.

PMID:
11388704
29.

Prodigiosin induces cell death and morphological changes indicative of apoptosis in gastric cancer cell line HGT-1.

Díaz-Ruiz C, Montaner B, Pérez-Tomás R.

Histol Histopathol. 2001 Apr;16(2):415-21. doi: 10.14670/HH-16.415.

PMID:
11332697
30.

Prodigiosin from the supernatant of Serratia marcescens induces apoptosis in haematopoietic cancer cell lines.

Montaner B, Navarro S, Piqué M, Vilaseca M, Martinell M, Giralt E, Gil J, Pérez-Tomás R.

Br J Pharmacol. 2000 Oct;131(3):585-93.

31.
32.
33.

Immunochemical study of transforming growth factor-beta in the kidney of the rat and chicken.

Díaz-Ruiz C, Montaner B, Pérez-Tomás R.

Histochem Cell Biol. 1996 Jun;105(6):475-8.

PMID:
8791107

Supplemental Content

Loading ...
Support Center